Sort
30,917 grants matching “tumor microenvironment”
Crosstalk between EGFR and TEAD Activity Directs Migration in Human Glioblastoma
$370,781Nadejda Mincheva Tsankova · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · NS
The Role of Proteases and Peptides in Cancer Pain
$370,740Brian L Schmidt · New York University · R01 · FY2011 · DE
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer
$370,726Jeffrey Victor Ravetch · Rockefeller University · R01 · FY2025 · CA
Clinical study of GMCI in Pancreatic Cancer
$370,718Estuardo Aguilar-Cordova · Advantagene, Inc · R43 · FY2006 · CA
Bioengineering approaches to map mechanotransduction in the living cell
$370,714Ning Wang · University Of Illinois At Urbana-Champaign · R01 · FY2018 · GM
Computational model of targeted drug delivery
$370,700Dieter Haemmerich · Medical University Of South Carolina · R01 · FY2022 · CA
Project 04 - Develop a portfolio of agents for switching that match biology of residual tumor burden
$370,660Douglas Yee · University Of California, San Francisco · P01 · FY2019 · CA
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer
$370,628Xiaolin Zi · University Of California-Irvine · R01 · FY2022 · CA
Multiscale Image-based Modeling of Antiangiogenic Resistance in Breast Cancer
$370,575Arvind P Pathak · Johns Hopkins University · R01 · FY2018 · CA
Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors
$370,575Timothy Anthony Yap · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression
$370,575Guocan Wang · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Novel tumorigenic mechanisms of the LKB1 tumor suppressor
$370,575Diego H Castrillon · Ut Southwestern Medical Center · R01 · FY2017 · CA
Multiscale Image-based Modeling of Antiangiogenic Resistance in Breast Cancer
$370,575Arvind P Pathak · Johns Hopkins University · R01 · FY2017 · CA
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
$370,575Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
$370,575Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Targeting extracellular matrix-cancer stem cell interactions in pancreatic cancer
$370,575William H Matsui · Johns Hopkins University · R01 · FY2017 · CA
Paradoxical roles of tumor lymphangiogenesis on tumor immunity and implications for immunotherapy - Resubmission 01
$370,575Melody A Swartz · University Of Chicago · R01 · FY2018 · CA
Role of SAP30 in hypoxia inducible factor activation and breast cancer progression
$370,575Weibo Luo · Ut Southwestern Medical Center · R01 · FY2020 · CA
Role of SAP30 in hypoxia inducible factor activation and breast cancer progression
$370,575Weibo Luo · Ut Southwestern Medical Center · R01 · FY2021 · CA
Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.
$370,575Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Novel tumorigenic mechanisms of the LKB1 tumor suppressor
$370,575Diego H Castrillon · Ut Southwestern Medical Center · R01 · FY2020 · CA
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
$370,575Juan Fueyo · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Jagged1-dependent tumor-stromal interactions in bone metastasis
$370,575Yibin Kang · Princeton University · R01 · FY2021 · CA
Role of SAP30 in hypoxia inducible factor activation and breast cancer progression
$370,575Weibo Luo · Ut Southwestern Medical Center · R01 · FY2019 · CA
Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
$370,575Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA